Sun Pharma: Other income saves the day - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sun Pharma: Other income saves the day

Aug 26, 2003

Speciality pharma company, Sun Pharma has announced its June quarter results recently. The company has reported a 9% increase in topline and a 14% growth in bottomline. While the operating profit margins declined, sharp growth in the other income has helped the company improve its net profit margins. In this context, let us review the performance of the company.

Results analysis
(Rs m)1QFY031QFY04Change
Net Sales 1,901 2,074 9.1%
Other Income 19 90 374.7%
Expenditure 1,340 1,518 13.3%
Operating Profit (EBDIT) 561 556 -1.0%
Operating Profit Margin (%)29.5%26.8% 
Depreciation 50 53 6.5%
Profit before Tax53159311.8%
Tax 50 46 -8.0%
Profit after Tax/(Loss) 480 547 13.9%
Net profit margin (%)25.3%26.4% 
No. of Shares 93.6 92.9  
Diluted Earnings per share*20.523.6 
P/E Ratio  19.9  
(* annualised)   

Let us briefly understand the performance of the different business segments of the company.

Exports were the key growth driver for the company. On the domestic front, although the generics business grew by a sharp 14%, domestic formulations business recorded a marginal growth. The core therapeutic segments of psychiatry, neurology, cardiology, diabetology and gastroenterology (contributing 72% of domestic formulation sales) grew in the range of 17 to 20%. The company has projected a growth of 10-15% in the domestic formulations business in FY04. On the exports front, the growth was fuelled by a sharp growth in the export of formulations. For FY04, Sun Pharma has given a growth guidance of 40% in the export of formulations.

Sales break-up
(Rs m)1QFY031QFY04ChangeContribution to
total revenues
Formulations 1,262 1,288 2.1%66.4%
Generics304 347 14.2%16.0%
Others2 0 -0.1%
Total (A) 1,567 1,635 4.3%82.4%
Formulations71 112 56.4%3.8%
Generics259 318 22.8%13.6%
Others3 8 -0.2%
Total (B) 334 439 31.4%17.6%
Grand Total ((A)+(B)) 1,901 2,074 9.1%100.0%

Although, Sun Pharma recorded a marginal growth in topline, a sharp rise in staff cost and other expenditure has adversely affected the operating profit margins of the company. The rise in the staff cost is on account of an increase in the R&D personnel, while other expenditure has increased due to the fact that it includes expenditure incurred on sales made in the previous quarter. Despite the drop in the operating profits, a sharp increase in the other income coupled with a drop in the tax provision helped Sun Pharma register a 14% growth in net profits. The other income increased on account of the receipt of Rs 42 m as share of income from ‘Sun Pharmaceutical Industries” a partnership firm engaged in the manufacture of formulations.

Expenditure break up
(Rs m)1QFY031QFY04Change
Staff cost12116435.1%
Indirect cost20324319.8%
Other expenses28234020.4%
Total 1,340 1,518 13.3%

On the R&D front, Sun Pharma has incurred R&D expenditure of Rs 91 m in 1QFY04 as against Rs 61 m in the corresponding previous quarter. The company plans to focus of four broad platform technologies - targeted drug delivery system, biodegradable injectibles system, dry powder inhaler system and control release oral product. Sun Pharma expects its 1st NCE to be synthesized by 2005.

Sun Pharma ‘s associate company (49.39% stake), Caraco has posted a 111% topline growth to US$ 11 m during June quarter 2003 and net profits of US$ 4.3 m as against a net loss of US$ 1.9 m during the corresponding previous quarter. For the first six months of year 2003, Caraco has recorded sales of US$ 20.6 m and net profits of US$ 6.5 m. The company’s policy of sourcing part of its 3 bulk drugs requirements from Sun Pharma has resulted in a sharp drop in the raw material cost and a consequent improvement in performance.

Sun Pharma is currently trading at Rs 469, implying a P/E of 20x its annualised 1QFY04 earnings. The turnaround in the associate company, Caraco is a big plus for the company. Although, the company is now gradually increasing its exports thrust, since most of its revenues are still generated from the domestic markets, its performance going forward could be influenced by the government’s drug pricing policy and intense competition prevalent in the domestic markets. Also, the domestic performance of the company during the quarter is concerning.

Equitymaster requests your view! Post a comment on "Sun Pharma: Other income saves the day". Click here!


More Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Sun Pharma's Stock Falls 4% After Its March Quarter Results (Views On News)

May 28, 2021

In the past three months, the stock has outperformed the market by gaining nearly 20%. Can it go higher?

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 12:22 PM


  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks